Most Read Articles
Stephen Padilla, Yesterday
The novel coronavirus disease (COVID-19) pandemic appears to have a significant impact on oncological care, according to a study, which stresses the need for psycho-oncological support for cancer patients.
01 Aug 2020
Supplementation with probiotics may have positive effects in patients with type 2 diabetes mellitus (T2DM), reports a recent meta-analysis.
01 Aug 2020
Ensituximab, a chimeric monoclonal antibody targeting a variant of MUC5AC, shows modest clinical activity with good safety profile in patients with refractory colorectal cancer, according to data from a phase II study.
Roshini Claire Anthony, 30 Jul 2020

Frailty may indicate an increased risk of death from COVID-19, results of the COPE* study showed.

S100A4 level predicts progression, mortality in idiopathic pulmonary fibrosis

03 Jul 2020

Serum levels of S100 calcium‐binding protein A4 (S100A4) appear to be a helpful biomarker in predicting disease progression or mortality in patients with idiopathic pulmonary fibrosis (IPF), suggests a recent study.

Serum S100A4 levels were detectable in 26 (27.3 percent) of 95 IPF patients but were undetectable in all healthy controls (p<0.01). Aggregation of numerous S100A4‐expressing cells around the fibroblastic foci and mature fibrotic regions were shown in immunostaining of lung tissues from IPF patients.

Of note, prognosis was significantly worse in IPF patients with higher serum S100A4 levels than those with lower serum levels (2-year cumulative survival rate, 41.7 percent vs 77.0 percent; p<0.01). Multivariate analyses also revealed that baseline serum S100A4 levels (per 10 ng/mL increase) independently correlated with higher disease progression rate (odds ratio, 1.06; p=0.01) and higher mortality (hazard ratio, 1.18; p=0.03).

“Our findings may help establish treatment strategies for IPF,” the authors said.

This study measured serum S100A4 levels in 95 consecutive IPF patients and 50 healthy controls via enzyme-linked immunosorbent assay. The authors determined S100A4 expression in lung tissues using immunohistochemistry/immunofluorescence and its association with disease progression, defined as deterioration in lung function or death. Finally, Kaplan-Meier method and Cox hazard analysis were used to assess mortality.

“IPF is a progressive interstitial lung disease with a poor prognosis,” the authors said. “S100A4 is considered as a marker of fibroblasts … but its clinical application remains to be investigated.”

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, Yesterday
The novel coronavirus disease (COVID-19) pandemic appears to have a significant impact on oncological care, according to a study, which stresses the need for psycho-oncological support for cancer patients.
01 Aug 2020
Supplementation with probiotics may have positive effects in patients with type 2 diabetes mellitus (T2DM), reports a recent meta-analysis.
01 Aug 2020
Ensituximab, a chimeric monoclonal antibody targeting a variant of MUC5AC, shows modest clinical activity with good safety profile in patients with refractory colorectal cancer, according to data from a phase II study.
Roshini Claire Anthony, 30 Jul 2020

Frailty may indicate an increased risk of death from COVID-19, results of the COPE* study showed.